Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma

K. L. Moek; W. M. Fiedler; J. C. von Einem; H. M. Verheul; T. Seufferlein; D. J. de Groot; V. Heinemann; M. Kebenko; C. W. Menke-van der Houven van Oordt; T. J. Ettrich; E. Rasmussen; P. Bogner; B. Sable; S. Stienen; E. G.E. de Vries

doi:https://doi.org/10.1093/annonc/mdy279.414

Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma

K. L. Moek, W. M. Fiedler, J. C. von Einem, H. M. Verheul, T. Seufferlein, D. J. de Groot, V. Heinemann, M. Kebenko, C. W. Menke-van der Houven van Oordt, T. J. Ettrich, E. Rasmussen, P. Bogner, B. Sable, S. Stienen, E. G.E. de Vries

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	viii139-viii140
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy279.414
Publication status	Published - 1 Oct 2018

Access to Document

https://doi.org/10.1093/annonc/mdy279.414

Cite this

Moek, K. L., Fiedler, W. M., von Einem, J. C., Verheul, H. M., Seufferlein, T., de Groot, D. J., Heinemann, V., Kebenko, M., Menke-van der Houven van Oordt, C. W., Ettrich, T. J., Rasmussen, E., Bogner, P., Sable, B., Stienen, S., & de Vries, E. G. E. (2018). Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii139-viii140. https://doi.org/10.1093/annonc/mdy279.414

@article{369d8ada5c114a4282afc9f45dc8ce7f,

title = "Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma",

author = "Moek, {K. L.} and Fiedler, {W. M.} and {von Einem}, {J. C.} and Verheul, {H. M.} and T. Seufferlein and {de Groot}, {D. J.} and V. Heinemann and M. Kebenko and {Menke-van der Houven van Oordt}, {C. W.} and Ettrich, {T. J.} and E. Rasmussen and P. Bogner and B. Sable and S. Stienen and {de Vries}, {E. G.E.}",

year = "2018",

month = oct,

day = "1",

doi = "https://doi.org/10.1093/annonc/mdy279.414",

language = "English",

volume = "29",

pages = "viii139--viii140",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

Moek, KL, Fiedler, WM, von Einem, JC, Verheul, HM, Seufferlein, T, de Groot, DJ, Heinemann, V, Kebenko, M, Menke-van der Houven van Oordt, CW, Ettrich, TJ, Rasmussen, E, Bogner, P, Sable, B, Stienen, S & de Vries, EGE 2018, 'Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii139-viii140. https://doi.org/10.1093/annonc/mdy279.414

Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma. / Moek, K. L.; Fiedler, W. M.; von Einem, J. C. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii139-viii140.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma

AU - Moek, K. L.

AU - Fiedler, W. M.

AU - von Einem, J. C.

AU - Verheul, H. M.

AU - Seufferlein, T.

AU - de Groot, D. J.

AU - Heinemann, V.

AU - Kebenko, M.

AU - Menke-van der Houven van Oordt, C. W.

AU - Ettrich, T. J.

AU - Rasmussen, E.

AU - Bogner, P.

AU - Sable, B.

AU - Stienen, S.

AU - de Vries, E. G.E.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85073560933&partnerID=8YFLogxK

U2 - https://doi.org/10.1093/annonc/mdy279.414

DO - https://doi.org/10.1093/annonc/mdy279.414

M3 - Article

C2 - 32136218

SN - 0923-7534

VL - 29

SP - viii139-viii140

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

Moek KL, Fiedler WM, von Einem JC, Verheul HM, Seufferlein T, de Groot DJ et al. Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii139-viii140. doi: https://doi.org/10.1093/annonc/mdy279.414

Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma

Access to Document

Other files and links

Cite this